Investors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Posted by Stanley Muller on Jul 1st, 2026

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors purchased 22,307 call options on the stock. This represents an increase of 48% compared to the average volume of 15,028 call options.

Analyst Ratings Changes

RXRX has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Morgan Stanley lifted their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, JPMorgan Chase & Co. reduced their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.10.

Read Our Latest Analysis on RXRX

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total value of $110,400.00. Following the completion of the transaction, the director owned 6,169,863 shares of the company’s stock, valued at $22,705,095.84. The trade was a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 121,937 shares of company stock worth $421,574 over the last 90 days. 6.65% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $31,000. Integral Investment Advisors Inc. bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $39,000. Sequoia Financial Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $41,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth $41,000. Finally, Allworth Financial LP boosted its position in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after acquiring an additional 4,403 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

Shares of RXRX stock remained flat at $3.67 during trading hours on Wednesday. 35,676,403 shares of the company were exchanged, compared to its average volume of 17,859,932. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -3.06 and a beta of 1.04. The company’s fifty day simple moving average is $3.30 and its 200-day simple moving average is $3.67. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. During the same period in the previous year, the business posted ($0.50) EPS. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. On average, equities analysts anticipate that Recursion Pharmaceuticals will post -0.99 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.